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Approximately one third of newly treated epilepsy patients do not respond to antiepileptic drugs (AEDs).
Overexpression of P-glycoprotein (P-gp) efﬂux transporter has been proposed to have a critical role in
causing resistance to AEDs. P-gp is a product of the ATP-binding cassette subfamily B member 1 (ABCB1)
gene. The purpose of this study was to investigate a possible link between ABCB1 rs3789243 C > T,
C1236T, G2677T/A, rs6949448 C > T, and C3435T haplotypes with response to carbamazepine (CBZ) or
sodium valproate (VPA) monotherapy in Malaysian epilepsy patients. No ABCB1 haplotype association
was found with response to either CBZ or VPA monotherapy in the Chinese, Indian, and Malay patients.
C3435 allele carriers of the Indian males with cryptogenic epilepsy were more prone to resistance to
either CBZ or VPA than carriers of T allele. Moreover, rs3789243T allele carriers of Malay females with
symptomatic epilepsy were more resistant to either CBZ or VPA than C allele carriers. Our ﬁndings
suggest that the ABCB1 rs3789243 C > T, C1236T, G2677T/A, rs6949448 C > T, and C3435T haplotypes
do not contribute to response to AED treatment in epilepsy.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Approximately, one third of patients with epilepsy do not
respond to antiepileptic drugs (AEDs) and it has been hypothesized
that this is due to over-expression of the multidrug-transporter.
Overexpression of P-glycoprotein (P-gp) has been reported to play
an important role in refractoriness to AEDs.1,2 This protein
functions as a transmembrane efﬂux pump, by moving drugs
from the intracellular to the extracellular domain. It is a product of
the ATP-binding cassette subfamily B member 1 (ABCB1) gene.3 It
has been hypothesized that genetic variation may be involved in
resistance to treatment. The most common polymorphisms of
ABCB1 gene are C1236T (rs1128503), G2677T/A (rs2032582), and
C3435T (rs1045642), and from these three, the C3435T polymor-
phism has received the most attention as a critical variant in
resistance to AEDs. Several pharmacogenomics studies have
demonstrated an association between ABCB1 C3435T polymor-
phism and resistance to AEDs treatment.4 However, our meta-
analysis involving 6864 subjects comprising Asian and Caucasian
patients, and controls, did not verify this hypothesis.5* Corresponding author. Tel.: +60 3 6255419; fax: +60 3 79674791.
E-mail address: batoolsadat@yahoo.com (B.S. Haerian).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.04.003Some studies have indicated that the C3435T locus may have an
effect on response to treatment through linkage disequilibrium
(LD) with other ABCB1 variants in a haplotype block. The authors
assessed the association of ABCB1 haplotypes derived from
C1236T, G2677T/A, and C3435T loci in response to AEDs in
different epilepsy populations. However, our haplotype meta-
analysis did not conﬁrm these results.6 Two studies examined the
possible linkage between C3435T locus and some other loci of
ABCB1 gene such as rs6949448 C > T and rs3789243 C > T, and one
of these studies reported positive results.7,8 Here, we addressed the
question of whether ABCB1 rs3789243 C > T, C1236T, G2677T/A,
rs6949448 C > T, and C3435T haplotypes are associated with
response to treatment in the Malaysian Chinese, Indian, and Malay
populations with epilepsy. We also meta-analyzed the pooled
studies including our data.
2. Methodology
2.1. Subjects
The present retrospective study is part of an ongoing multi-
centre cooperation between the University of Malaya Medical
Centre and the Universiti Kebangsaan Malaysia Medical Centre.
The study protocol was approved by the ethics committees of thevier Ltd. All rights reserved.
Table 1
Genotypes and allele frequencies of ABCB1 polymorphisms of drug-resistant (n = 323) and drug-responsive (n = 362) epilepsy patients in three ethnic subgroups of the
Malaysian population.
Allele/genotype Chinese (n = 277) Indian (n = 160) Malay (n = 248) Total (685)
NR (%) R (%) NR (%) R (%) NR (%) R (%) NR (%) R (%)
rs3789243 C > T
C 163 (62) 179 (61) 94 (70) 120 (64) 142 (57) 157 (64) 399 (62) 456 (63)
T 99 (38) 113 (39) 40 (30) 66 (36) 108 (43) 89 (36) 247 (38) 268 (37)
CC 53 (40) 57 (39) 34 (51) 38 (41) 40 (32) 51 (41) 127 (39) 146 (40)
CT 57 (44) 65 (45) 26 (39) 44 (47) 62 (50) 55 (45) 145 (45) 164 (45)
TT 21 (16) 24 (16) 7 (10) 11 (12) 23 (18) 17 (14) 51 (16) 52 (14)
1236 C > T
C 113 (43) 122 (42) 59 (44) 84 (45) 111 (44) 95 (39) 283 (44) 301 (42)
T 149 (57) 170 (58) 75 (56) 102 (55) 139 (56) 151 (61) 363 (56) 423 (58)
CC 27 (21) 28 (19) 14 (21) 20 (22) 24 (18) 22 (18) 65 (20) 70 (19)
CT 59 (45) 66 (45) 31 (46) 44 (47) 63 (46) 51 (41) 153 (47) 161 (45)
TT 45 (34) 52 (36) 22 (33) 29 (31) 38 (36) 50 (41) 105 (33) 131 (36)
2677 G > T
G 144 (55) 144 (49) 49 (37) 84 (45) 138 (55) 125 (51) 331 (51) 353 (49)
T 118 (45) 148 (51) 85 (63) 102 (55) 112 (45) 121 (49) 315 (49) 371 (51)
GG 36 (27) 35 (24) 8 (12) 18 (19) 39 (31) 25 (20) 83 (26) 78 (22)
GT 72 (55) 74 (51) 33 (49) 48 (52) 60 (48) 75 (61) 165 (51) 197 (54)
TT 23 (18) 37 (25) 26 (39) 27 (29) 26 (21) 23 (19) 75 (23) 87 (24)
rs6949448 C > T
C 190 (68) 166 (57) 60 (45) 97 (51) 158 (63) 146 (59) 389 (60) 409 (56)
T 91 (32) 126 (43) 74 (55) 89 (49) 92 (37) 100 (41) 257 (40) 315 (44)
CC 52 (40) 50 (34) 10 (15) 27 (29) 54 (43) 42 (34) 116 (36) 119 (33)
CT 67 (51) 66 (45) 40 (60) 43 (46) 50 (40) 62 (50) 157 (49) 171 (47)
TT 12 (9) 30 (21) 17 (25) 23 (25) 21 (17) 19 (15) 50 (15) 72 (20)
3435 C > T
C 147 (56) 167 (57) 78 (58) 89 (48) 151 (60) 144 (58) 376 (58) 400 (55)
T 115 (44) 125 (43) 56 (42) 97 (52) 99 (40) 102 (42) 270 (42) 324 (45)
CC 39 (30) 49 (34) 23 (34) 17 (18) 47 (38) 44 (36) 109 (34) 110 (30)
CT 69 (53) 69 (47) 32 (48) 55 (59) 57 (46) 56 (45) 158 (49) 180 (50)
TT 23 (18) 28 (19) 12 (18) 21 (23) 21 (17) 23 (19) 56 (17) 72 (20)
Abbreviations: NR, drug-resistant; R, drug-responsive.
B.S. Haerian et al. / Seizure 20 (2011) 546–553 547two centres. In the previous study we reported the inclusion and
exclusion criteria and deﬁnition of drug-resistance and drug-
responsiveness for 685 recruited patients from the epilepsy clinics.9
The previous data of ABCB1 C1236T, G2677T/A, and C3435T
polymorphisms was used for the current haplotype analysis and
adding on to the data from the rs3789243 C > T and rs6949448 C > T
loci. Real-time PCR analysis of rs3789243 C > T and rs6949448 C > T
loci was carried out using the Applied Biosystem Assay on Demand
reagents (Applied Biosystem, CA, USA).
2.2. Statistical methods
A goodness-of-ﬁt x2 test with one degree of freedom was
applied to test Hardy–Weinberg equilibrium (HWE) of the three
polymorphisms; p < 0.05 indicated a lack of agreement with HWE.
Association of alleles and genotypes with response to CBZ or VPA
monotherapy was calculated with binary logistic regression. The
odds ratios (ORs) with 95% conﬁdence intervals (CIs), adjusted for
confounders (ethnicity, drug type, gender, age at recruitment,
onset age of epilepsy, seizure type, and etiology of epilepsy.
The alternative genetic models for the ABCB1 C1236T, G2677T/
A, and C3435T polymorphisms were previously reported, but the
present meta-analysis includes rs3789243 C > T and rs6949448
C > T loci for both alleles (C vs. T) and genotypes, for codominant
(C/C vs. T/T and C/T vs. T/T), dominant (C/C + C/T vs. T/T), and
recessive (C/C vs. C/T + T/T) models. Haplotype and LD analysis for
the ﬁve ABCB1 polymorphisms was performed with the Haploview
4.2 program and corrected for multiple testing using 100,000
permutations for individual locus and haplotypes. Bonferroni’s
method was used for correction of multiple comparisons. Two-
sided tests of statistical signiﬁcance were used to determine
statistically signiﬁcant p values (p < 0.05) with the SPSS software
package (ver. 15.0; SPSS, Chicago, IL, USA).2.3. Meta-analysis
Published studies until November 2010 that determined the
distribution of the ABCB1 rs3789243 C > T and rs6949448 C > T
genotype in epilepsy patients and healthy people were included in
this meta-analysis with no language limitation. Pooled ORs with
95% CIs and p values were calculated for the ABCB1 rs3789243
C > T and rs6949448 C > T polymorphisms under alternative
genetic models. To measure the strength of genetic association, we
used the I2 test to assess the proportion of statistical heterogeneity
and the Q-statistic test with p  0.10 to deﬁne a signiﬁcant degree
of heterogeneity. Fixed effects were calculated as the inverse
variance weighted average of the log OR if there was no
heterogeneity and random effects were calculated when there
was substantial heterogeneity. Statistical analyses were performed
using validated Meta-analysis Made Easy (MIX) version 1.7.10
3. Results
The patients’ demographic features were previously reported.9
Table 1 lists the allele and genotype percentages of the ABCB1
frequencies of rs3789243 C > T, 1236 C > T, 2677G > T, rs6949448
C > T, and 3435 C > T polymorphisms from 685 epilepsy patients.
Crs3789243 allele was more frequent than the T-allele in the
Chinese (62%), Indians (67%), and Malays (61%). However, C1236
allele was less common than T-allele in the Chinese (43%), Indians
(45%), and Malays (42%). Both G2677 and Crs6949448 alleles were
more frequent in the Chinese (52 and 63%, respectively) and Malay
(53 and 61%, respectively) patients than minor alleles compared
with Indians (48 and 41%, respectively). Finally, C3435 allele was
more common than T allele in the Chinese (57%), Indian (53%), and
Malay (59%) patients.
Table 2
Genotypes and allele frequencies of ABCB1 polymorphisms in drug-resistant (n=323) and drug-responsive (n=362) epilepsy patients in the pooled population studied and in the three ethnic subgroups of the Malaysian population
under alternative genetic models.
Genotype Ethnicity
Chinese (n=277) Indian (n=160) Malay (n=248) Total (685)
NR R p ORa (CI 95%) NR R p ORa (CI 95%) NR R p ORa (CI 95%) NR R p ORa (CI 95%)
C1236T
C vs. T 262 292 0.56 0.89 (0.61–1.30) 134 186 0.86 1.04 (0.64–1.70) 250 246 0.12 0.72 (0.48–1.09) 646 724 0.29 0.88 (0.69–1.11)
C/C vs. T/T 72 80 0.63 0.82 (0.37–1.83) 36 49 0.89 1.07 (0.41–2.81) 62 72 0.19 0.57 (0.25–1.32) 170 201 0.30 0.77 (0.48–1.23)
C/T vs. T/T 104 118 0.76 0.91 (0.50–1.66) 53 73 0.97 0.99 (0.44–2.20) 101 101 0.09 0.57 (0.29–1.09) 258 292 0.30 0.82 (0.56–1.19)
C/C+C/T vs. T/T 131 146 0.61 0.87 (0.50–1.51) 67 93 0.95 1.02 (0.49–2.13) 125 123 0.08 0.59 (0.32–1.07) 323 362 0.25 0.81 (0.57–1.16)
C/C vs. C/T +T/T 131 146 0.66 0.86 (0.44–1.69) 67 93 0.82 1.11 (0.47–2.59) 125 123 0.54 0.79 (0.37–1.68) 323 362 0.61 0.90 (0.59–1.37)
rs6949448 C>T
C vs. T 262 292 0.09 0.72 (0.49–1.05) 134 186 0.25 1.33 (0.82–2.18) 250 246 0.59 0.89 (0.59–1.34) 646 724 0.47 0.91 (0.72–1.16)
C/C vs. T/T 64 80 0.11 2.12 (0.85–5.33) 27 50 0.34 1.67 (0.58–4.81) 75 61 0.98 1.01 (0.42–2.45) 166 191 0.72 1.10 (0.66–1.83)
C/T vs. T/T 79 96 0.08 0.47 (0.20–1.10) 57 66 0.48 1.36 (0.58–3.15) 71 81 0.13 1.89 (0.83–4.31) 207 243 0.66 0.90 (0.57–1.43)
C/C+C/T vs. T/T 131 146 0.06 0.46 (0.21–1.02) 67 93 0.96 0.98 (0.45–2.14) 125 123 0.34 1.45 (0.67–3.15) 323 362 0.62 0.89 (0.58–1.38)
C/C vs. C/T +T/T 131 146 0.30 1.34 (0.77–2.31) 67 93 0.05 2.49 (1.01–6.12) 125 123 0.12 0.62 (0.34–1.14) 323 362 0.50 1.13 (0.79–1.62)
G2677T
G vs. T 262 292 0.11 0.73 (0.50–1.07) 134 186 0.07 1.60 (0.97–2.65) 250 246 0.51 0.87 (0.58–1.31) 646 724 0.79 0.97 (0.76–1.23)
G/G vs. T/T 59 72 0.41 0.71 (0.32–1.61) 34 45 0.10 2.53 (0.82–7.78) 65 48 0.38 0.66 (0.26–1.68) 158 165 0.85 0.95 (0.58–1.57)
G/T vs. T/T 95 111 0.09 0.55 (0.27–1.10) 59 75 0.16 1.82 (0.79–4.19) 86 98 0.29 1.50 (0.71–3.21) 240 284 0.55 1.13 (0.75–1.72)
G/G vs. (G/T+T/T) 131 146 0.06 0.54 (0.28–1.04) 67 93 0.08 1.98 (0.91–4.30) 125 123 0.58 1.23 (0.59–2.53) 323 362 0.71 1.08 (0.73–1.59)
(G/G+G/T) vs. T/T 131 146 0.39 0.77 (0.42–1.40) 67 93 0.18 1.95 (0.73–5.19) 125 123 0.11 0.57 (0.28–1.13) 323 362 0.41 0.85 (0.57–1.26)
C3435T
C vs. T 262 292 0.33 1.02 (0.83–1.75) 134 186 0.13 0.69 (0.42–1.12) 250 246 0.74 0.93 (0.62–1.40) 646 724 0.71 0.96 (0.75–1.21)
C/C vs. T/T 62 77 0.36 0.69 (0.31–1.53) 35 38 0.08 0.37 (0.12–1.14) 68 67 0.72 0.86 (0.37–2.01) 165 182 0.62 1.13 (0.69–1.85)
C/T vs. T/T 92 97 0.93 0.97 (0.46–2.05) 44 76 0.49 1.40 (0.54–3.60) 78 79 0.59 0.80 (0.36–1.77) 214 252 0.97 0.99 (0.62–1.58)
C/C+C/T vs. T/T 131 146 0.64 0.85 (0.42–1.70) 67 93 0.85 0.92 (0.38–2.20) 125 123 0.60 0.82 (0.39–1.72) 323 362 0.93 1.02 (0.66–1.57)
C/C vs. C/T +T/T 131 146 0.29 0.74 (0.42–1.29) 67 93 0.02* 0.38 (0.16–0.86) 125 123 0.95 1.02 (0.55–1.87) 323 362 0.63 1.09 (0.76–1.57)
rs3789243 C>T
C vs. T 262 292 0.66 0.92 (0.63–1.34) 134 186 0.36 0.78 (0.46–1.33) 250 246 0.10 1.42 (0.93–2.15) 646 724 1.00 1.00 (0.78–1.28)
C/C vs. T/T 74 81 0.80 0.91 (0.42–1.96) 41 49 0.69 1.29 (0.37–4.50) 63 68 0.16 0.53 (0.22–1.29) 178 198 0.88 1.04 (0.63–1.72)
C/T vs. T/T 78 89 0.91 0.96 (0.43–2.11) 33 55 0.84 0.86 (0.21–3.47) 85 72 0.55 0.77 (0.32–1.82) 196 216 0.82 0.94 (0.57–1.57)
C/C+C/T vs. T/T 131 146 0.93 0.97 (0.47–1.98) 67 93 0.68 0.78 (0.24–2.51) 125 123 0.30 0.66 (0.30–1.46) 323 362 0.86 1.04 (0.65–1.66)
C/C vs. C/T +T/T 131 146 0.57 0.86 (0.50–1.47) 67 93 0.33 1.42 (0.70–2.91) 125 123 0.11 0.61 (0.33–1.12) 323 362 0.91 0.98 (0.70–1.38)
Abbreviations: NR, drug-resistant; R, drug-responsive.
a OR estimated odds ratio by binary logistic regression analysis adjusted for age at study, onset age at epilepsy, etiology, ethnicity, gender, drug type, and seizure type.
* After correction of multiple comparisons with Bonferroni’s correction for the Indians, this signiﬁcant association was lost (p=0.02>0.05/5).
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at onset of epilepsy, seizure type, drug type, and epilepsy
syndromes. No allelic association of ABCB1 variants was observed
with response to treatment in each ethnicity (Table 2). Stratiﬁed
analysis by ethnicity, gender, and etiology demonstrated a
signiﬁcant association between C3435 allele in the Indian males
with cryptogenic epilepsy and response to treatment (adjusted OR
0.17, CI 95% 0.037–0.80, p = 0.02). C3435 allele was more common
in the drug-resistant patients (75%) than drug-responsive subjects
(46%). Similarly, T-allele of rs3789243 locus was associated with
response to treatment in the Malay females with symptomatic
epilepsy (adjusted OR 0.25, 0.078–0.83, p = 0.02). T-allele was
more frequent in the drug-resistant patients (50%) compared with
drug-responsive subjects (19%). We also divided the etiology into
idiopathic generalized in 150 patients (23.2%) and localization-
related epilepsy in 497 subjects (all non-idiopathic generalized
epilepsy). Stratiﬁed analysis by ethnicity and etiology was
performed for all polymorphisms. No signiﬁcant allelic association
of every locus was observed with response to CBZ or VPA in each
ethnicity.
The genotype distribution of the ABCB1 polymorphisms in both
drug-resistant and drug-responsive patients in the total group or in
each ethnic subgroup was consistent with HWE. No signiﬁcant
association of ABCB1 polymorphisms was observed with response
to treatment in the Chinese and Malays under alternative genetic
models. However, the C3435T variant in the Indian subgroup
showed a signiﬁcant association with response to treatment
(adjusted OR 0.38, 95% CI 0.16–0.86, p = 0.02) as well as for
rs6949448 C > T at the marginal level (adjusted OR 2.49 95% CI
1.01–6.12, p = 0.05) under autosomal recessive model. After
correction of multiple comparisons with Bonferroni’s method,
we did not ﬁnd any signiﬁcant association between ABCB1
polymorphisms and response to treatment (0.05/5).
Table 3 lists the haplotypes of ABCB1 polymorphisms in the
drug-resistant and drug-responsive patients, encountered with
frequencies of above 3%. Overall, the CCGCC (19%) haplotype was
more frequent than other ABCB1 gene haplotypes. The ratio of
frequency of this haplotype to the mutant haplotype frequency
was 1.41. There was no signiﬁcant association between ABCB1
haplotypes and response to treatment in each ethnicity. Moreover,
no signiﬁcant association of rs3789243–1236–2677 (T–C–G),
rs3789243–2677–3435 (T–G–C), rs3789243–1236 (C–T),
rs3789243–2677 (T–G and T–G/A), and rs3789243–3435 (T–C)
haplotypes was observed with response to CBZ or VPA in each
ethnicity (Table 4).
Among diplotypes, CCGCC–TTTTT was more frequent in the
Indians and Malays but not in the Chinese. CCGCC–TTTTC
frequency in the Chinese patients was higher than other
diplotypes. No signiﬁcant association was observed between
ABCB1 diplotypes and response to treatment in each ethnicity.
The pairwise LD coefﬁcients D’ between ABCB1 polymorphisms in
the Chinese, Indian, and Malay drug-resistant and drug-responsive
patients have been shown in Fig. 1. There was diversity of LD
pattern between ethnicities as well as drug-resistant and drug-
responsive patients. A strong LD was observed between C3435T/
rs5949448 C > T in the Indian drug-resistant patients. Mostly, a
low LD was seen between G2677T–C1236T and C1236T/rs3789243
C > T polymorphisms but a moderate LD between rs5949448
C > T/G2677T in the Chinese and Malay drug-resistant and drug-
responsive patients.
Table 5 lists the results of meta-analysis of allele and genotype
of the ABCB1 frequencies of rs3789243 C > T and rs6949448 C > T
polymorphisms for epilepsy patients. There were 2 reports of the
rs3789243 C > T locus in the Asians and Caucasians and one report
from rs5949448 locus in the Asian epilepsy population. Meta-
analysis of the pooled data from previous reports and from this
Table 4
Haplotype frequency of ABCB1 polymorphisms within drug-resistant (n = 323) and drug-responsive (n = 362) epilepsy patients in the pooled population studied and in the
three ethnic subgroups.
Haplotypes Haplotypes Kwan et al. This study
Chinese Indian Malay
NR R p* NR R P* NR R P* NR R P*
Rs3789243–1236–2677 T–C–G 7.9 13.4 0.02 10.9 9.4 NS 14.4 17.2 NS 16.7 10.2 NS
Rs3789243–2677–3435 T–G–C 27 35.5 0.02 17.4 14.5 NS 18.9 16.2 NS 21.2 16 NS
Rs3789243–1236 C–T 42.3 33.8 0.01 33.4 34.4 NS 45.1 42.6 NS 32.2 41.1 NS
Rs3789243–2677 T–G 27.4 37.4 <0.01 25.7 21.2 NS 20.8 24.2 NS 28.6 21.5 NS
Rs3789243–2677 T–G/A 29.4 38.5 0.01 26.2 24.3 NS 25.2 27.8 NS 31.1 22.4 NS
Rs3789243–3435 T–C 28.7 36.3 0.04 25.9 25.6 NS 23.2 23.7 NS 32.5 21.1 NS
Abbreviations: NR, drug-resistant; R, drug-responsive; NS, not signiﬁcant.
* After 100,000 permutations.
Table 5
Allele and genotype meta-analysis of ABCB1 rs3789243 C > T and rs6949448 C > T polymorphisms among previous studies and the present study under alternative genetic
models.
Allele/genotype rs3789243 C > T (n = 1497) rs6949448 C > T (n = 1132)
NR (n = 634) vs. R (n = 863) I2 (%) p NR (n = 513) vs. R (n = 619) I2 (%) p
OR CI p OR CI p
G vs. A 1.20 0.93–1.54 0.16 70 <0.01 1.00 0.74–1.36 0.98 67 0.03
GG vs. AA 1.68 0.81–3.52 0.17 83 <0.01 0.90 0.62–1.31 0.58 77 <0.01
GA vs AA 1.69 0.85–3.36 0.50 82 <0.01 0.99 0.47–2.10 0.98 78 <0.01
GG + GA vs. AA 1.69 0.84–3.41 0.14 84 <0.01 0.99 0.49–2.01 0.97 77 <0.01
GG vs. GA + AA 1.15 0.95–1.39 0.14 33 0.14 1.00 0.66–150 0.98 59 0.06
Abbreviations: NR, drug-resistant; R, drug-responsive.
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showed no signiﬁcant association between alleles and alternative
genotype models with response to treatment. Therefore, these two
polymorphisms of ABCB1 do not contribute to response to AEDs. A
wide heterogeneity (33–84%) was observed among the studies of
drug-resistant patients versus drug-responsive group. Unlike the
recessive genotype model for rs3789243 C > T locus, heterogene-
ity was signiﬁcant for allele and other genotype patterns.
4. Discussion
To identify whether ABCB1 rs3789243 C > T, C1236T, G2677T/
A, rs6949448 C > T, and C3435T haplotypes polymorphisms and
their haplotypes contribute to response to treatment, we carried
out a study in Malaysian tri-ethnic patients with epilepsy as well as
performed a meta-analysis of the pooled data of rs3789243 C > T
and rs6949448 C > T loci. The results of this study showed no
haplotype association of these ABCB1 loci with response to CBZ or
VPA monotherapy. Meta-analysis data also showed no association
of rs6949448 C > T and rs3789243 C > T loci with response to
AEDs. Stratiﬁed analysis showed that C3435 allele carriers among
the Indian males with cryptogenic epilepsy were more prone to
resistance to either CBZ or VPA than the T allele carriers. Moreover,
rs3789243T allele carriers of the Malay females with symptomatic
epilepsy were more resistant to CBZ or VPA than C allele carriers.
Stratiﬁed analysis by ethnicity and etiology (idiopathic
generalized and localization-related epilepsy) showed no associ-
ation of ABCB1 polymorphisms with response to treatment.
Furthermore, we analyzed the ABCB1 rs3789243 C > T gene
polymorphism in LD with 1236 C > T, 2677 G > T/A, 2677 G/A > T
and 3435 C > T loci in the epilepsy patients. We did not ﬁnd any
association between rs3789243–1236–2677, rs3789243–2677–
3435, rs3789243–1236, rs3789243–2677, and rs3789243–3435
haplotypes and response to either CBZ or VPA in the Malaysian
Chinese, Indian, and Malays. Our negative ﬁnding of both allele
and haplotype analysis did not verify the previous report from
China.8 The plausible explanation for this inconsistency betweenthe data is polytherapy, sample size, and Chinese subethnicities.
Drug interaction or their competition for interaction with
common transporters, targets and metabolic mediators may have
an effect on the results. For example, VPA interacts with CBZ,
lamotrigine, and phenytoin.11 Therefore, we stringently selected
42% of all epilepsy patients who were on monotherapy to have a
homogenous population and obtain more reliable data. We
focused more on VPA and CBZ monotherapy as an inclusion
criterion, since these drugs are not only widely used in epilepsy
but also has a broad spectrum of activity.12 However, inclusion of
this criterion in the study caused smaller sample size especially in
the case of the Chinese patients (277) compared to a previous
study in which the sample size was 464 subjects who received a
wide variety of AEDs in a polytherapy regimen among which VPA
(25%), CBZ (23%), and PHT (16%) were the most commonly used
AEDs. It seems that our ﬁnding gives a clearer picture of the kind of
association that is being studied. Furthermore we applied
adjusted ORs strategy for various confounders including drug
type in this study to minimize the effects of these covariates on the
association study.
There is a debate in the literature that some AEDs such as CBZ
and VPA may not be substrates of P-gp.13,14 Our negative ﬁndings
in the Chinese and Malay patients who were on CBZ and VPA
monotherapy are in agreement with the main hypothesis and
suggest that these ABCB1 polymorphisms may not signiﬁcantly
contribute to response to CBZ and VPA in epilepsy. However,
positive allelic results in the C3435 allele carriers of Indians males
with cryptogenic and rs3789243T allele carriers of the Malay
females with symptomatic epilepsy are inconsistent with this
hypothesis. This ﬁnding suggests that although CBZ or VPA may
induce P-gp expression and function, this effect may indirectly
contribute through other mediators or in connection of these genes
with other genes and loci.15–17 Moreover, epigenetic factors can
also contribute to pharmacotherapy outcomes through histone
modiﬁcation and DNA methylation.18 Further studies are neces-
sary to ﬁnd the probable link between these factors with response
to CBZ or VPA.
Fig. 1. Illustration of the ABCB1 LD (D0) polymorphisms in the Chinese, Indian, and Malay drug-resistant (NR) and drug-responsive (R) patients Indicating rs1128503 (C1236T),
rs2032582 (G2677T), rs1045642 (C3435T).
B.S. Haerian et al. / Seizure 20 (2011) 546–553 551Treatment outcome may be inﬂuenced by a complex multi-
variant interaction via LD rather than at a single locus. It therefore
follows that analysis of LD between a locus with causal loci and
haplotype analysis would provide more useful information rather
than testing each polymorphic locus separately.16 In this study, LD
patterns of the ABCB1 loci varied among the ethnicities as well as
among drug-resistant and drug-responsive patients. There was a
strong LD between C3435T–rs5949448 in the Indian drug-resistant patients. Evidence has shown that despite of the
emergence of Asians from Europeans and Europeans from Africans,
frequency of genetic polymorphisms varies between these
populations. Since, prevalence of diseases varies among popula-
tions, so it is expected that the frequencies of genetic variants that
contribute to their causation also vary. Geographic and cultural
factors can cause genetic variation in different populations. This
could be contributed by natural selection in a speciﬁc local
Fig. 2. The 2 recombination hotspots of the ABCB1 gene: HS1 and HS2 (black bars). The ABCB1 C3435T locus is very close to HS1, the rs4949448 C > T and the G2677T/A
polymorphisms are farther away, while the C1236T locus lies midway between HS1 and HS2 and the rs3789243 C > T locus is located after HS2.
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subject to distinct environmental or cultural pressure, positive
selection may change the allele frequency in one population but
not in another.19–23 It is plausible therefore, that high variation of
these polymorphisms among different epilepsy patient popula-
tions is caused by these factors.
Other than drug transporters, drug response in epilepsy may
also depend on the multiple genes involved in the metabolism of
AEDs. Many AEDs are ﬁrst activated by phase I drug-
metabolizing enzymes such as cytochrome P450 (CYP), then
conjugated with ligands such as glucuronidases, and glutathione
synthetase by phase II drug-metabolizing enzymes. For example,
CYP and UDP-glucuronyltransferase (UGT) are involved in the
metabolism of CBZ and VPA. There is an interindividual variation
in the enzyme activity of these enzymes that can lead to
variability in drug responsiveness. Genetic polymorphisms of
drug metabolizing enzymes can inﬂuence the optimum dosage
requirement for each individual thereby resulting in treatment
failure due to inadequate drug levels affecting the metabolic
pathways of AEDs thereby affecting drug levels.24–27 The
frequency of variant alleles for drug metabolizing enzymes
differs among ethnic groups. For example, CYP2D6 metabolizes
approximately 25% of drugs such as antidepressants. There is an
interethnic variability in the CYP2D6 allele, resulting in
expression and activity difference of this gene.28,29 Taking into
account of the functional variants in the relevant genes encoding
the metabolizing enzymes may be important for predicting
metabolism of the AEDs concerned thereby improving respon-
siveness to AED treatment.
Finally, another cause of difference of our results with the
previous data may be due to the proximity of some variants such as
C3435T to the ﬁrst hotspot and rs3789243 C > T to the second
hotspot of ABCB1 gene (http://snp.cshl.org/cgi-perl/gbrowse/
hapmap21_B35/, Fig. 2) where crossing- over happens. According-
ly, crossing-over events in this hotspot may not only be involved
with high variation of C3435T locus but also that the location of
this hotspot may vary among the patient populations of the studies
in epilepsy.6In conclusion, this study failed to show any association between
the ABCB1 rs3789243 C > T, C1236T, G2677T/A, rs6949448 C > T,
and C3435T haplotypes with response to CBZ or VPA monotherapy
in the Malaysian tri-ethnic groups. However, C3435 allele carriers
of the Indian males with cryptogenic epilepsy were more prone to
resistance to CBZ or VPA than T allele. Moreover, rs3789243T allele
carriers of the Malay females with symptomatic epilepsy were
more resistant to either CBZ or VPA than C allele carriers. Our
ﬁndings suggest that ABCB1 haplotypes of these loci may not
contribute to response to drug treatment in epilepsy.
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